Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

This study has been completed.

Sponsored by:	Eli Lilly and Company
Information provided by:	Eli Lilly and Company
ClinicalTrials.gov Identifier:	NCT00036088

Purpose

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Condition	Intervention	Phase
Schizophrenia	Drug: Olanzapine	Phase IV

MedlinePlus related topics: Schizophrenia

Drug Information available for: Olanzapine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Eli Lilly and Company:

Estimated Enrollment:	530
Study Start Date:	August 2001
Estimated Study Completion Date:	July 2002

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion:

You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
You must have been diagnosed with schizophrenia
You must be able to visit the doctor's office as scheduled for the next 7 months

Exclusion:

You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
You are either pregnant or breastfeeding

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00036088

Show 60 Study Locations

Sponsors and Collaborators

Eli Lilly and Company

More Information

Study ID Numbers:	2347, F1D-MC-HGHJ
Study First Received:	May 7, 2002
Last Updated:	July 18, 2006
ClinicalTrials.gov Identifier:	NCT00036088
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Schizophrenia
Mental Disorders
Olanzapine

Psychotic Disorders
Serotonin
Schizophrenia and Disorders with Psychotic Features

Additional relevant MeSH terms:

Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Gastrointestinal Agents
Psychotropic Drugs
Antiemetics
Central Nervous System Depressants

Antipsychotic Agents
Serotonin Uptake Inhibitors
Pharmacologic Actions
Serotonin Agents
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009